Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 359

1.

Coupling Computational and Intracellular Screening and Selection Towards Co-compatible cJun and cFos Antagonists.

Lathbridge A, Michalowska AS, Mason JM.

Biochemistry. 2019 Dec 5. doi: 10.1021/acs.biochem.9b00631. [Epub ahead of print]

PMID:
31804811
2.

Non-enzymatic roles of human RAD51 at stalled replication forks.

Mason JM, Chan YL, Weichselbaum RW, Bishop DK.

Nat Commun. 2019 Sep 27;10(1):4410. doi: 10.1038/s41467-019-12297-0.

3.
4.

PROCalcitonin-based algorithm for antibiotic use in Acute Pancreatitis (PROCAP): study protocol for a randomised controlled trial.

Siriwardena AK, Jegatheeswaran S, Mason JM, Baltatzis M, Chan A, Sheen AJ, O'Reilly D, Jamdar S, Deshpande R, de Liguori Carino N, Satyadas T, Qamruddin A, Hayden K, Parker MJ, Butler J, Rajai A, McIntyre B.

Trials. 2019 Jul 29;20(1):463. doi: 10.1186/s13063-019-3549-3.

5.

Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles.

Meade RM, Fairlie DP, Mason JM.

Mol Neurodegener. 2019 Jul 22;14(1):29. doi: 10.1186/s13024-019-0329-1. Review.

6.

Combining Constrained Heptapeptide Cassettes with Computational Design To Create Coiled-Coil Targeting Helical Peptides.

Lathbridge A, Mason JM.

ACS Chem Biol. 2019 Jun 21;14(6):1293-1304. doi: 10.1021/acschembio.9b00265. Epub 2019 Jun 5.

PMID:
31117396
7.

Mini-Sternotomy Versus Conventional Sternotomy for Aortic Valve Replacement.

Hancock HC, Maier RH, Kasim AS, Mason JM, Murphy GJ, Goodwin AT, Owens WA, Kirmani BH, Akowuah EF.

J Am Coll Cardiol. 2019 May 21;73(19):2491-2492. doi: 10.1016/j.jacc.2019.03.462. No abstract available.

PMID:
31097171
8.

Excitation-Energy-Dependent Molecular Beacon Detects Early Stage Neurotoxic Aβ Aggregates in the Presence of Cortical Neurons.

Gulácsy CE, Meade R, Catici DAM, Soeller C, Pantos GD, Jones DD, Alibhai D, Jepson M, Valev VK, Mason JM, Williams RJ, Pudney CR.

ACS Chem Neurosci. 2019 Mar 20;10(3):1240-1250. doi: 10.1021/acschemneuro.8b00322. Epub 2018 Nov 21.

PMID:
30346718
9.

Computational Competitive and Negative Design To Derive a Specific cJun Antagonist.

Lathbridge A, Mason JM.

Biochemistry. 2018 Oct 23;57(42):6108-6118. doi: 10.1021/acs.biochem.8b00782. Epub 2018 Oct 11.

PMID:
30256622
10.

Authors' response to the letter re: Evidence based treatment for unstable slipped upper femoral epiphysis: Systematic review and exploratory patient level analysis.

Alshryda S, Tsang K, Chytas A, Choudhry M, Sacchi K, Ahmad M, Mason JM.

Surgeon. 2019 Feb;17(1):58-60. doi: 10.1016/j.surge.2018.04.002. Epub 2018 Jun 25. No abstract available.

PMID:
29954672
11.

Chromosome ends as adaptive beginnings: the potential role of dysfunctional telomeres in subtelomeric evolvability.

Mason JMO, McEachern MJ.

Curr Genet. 2018 Oct;64(5):997-1000. doi: 10.1007/s00294-018-0822-z. Epub 2018 Mar 27. Review.

PMID:
29589105
12.

Mild Telomere Dysfunction as a Force for Altering the Adaptive Potential of Subtelomeric Genes.

Mason JMO, McEachern MJ.

Genetics. 2018 Feb;208(2):537-548. doi: 10.1534/genetics.117.300607. Epub 2017 Dec 14.

13.

The need for longer time horizons for cost-utility evaluation in bullous pemphigoid: reply from the authors.

Mason JM, Williams HC, Wojnarowska F.

Br J Dermatol. 2018 Mar;178(3):810. doi: 10.1111/bjd.16222. Epub 2018 Feb 7. No abstract available.

PMID:
29205265
14.

Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial.

Mason JM, Chalmers JR, Godec T, Nunn AJ, Kirtschig G, Wojnarowska F, Childs M, Whitham D, Schmidt E, Harman K, Walton S, Chapman A, Williams HC; U.K. Dermatology Clinical Trials Network BLISTER Study Group.

Br J Dermatol. 2018 Feb;178(2):415-423. doi: 10.1111/bjd.16006. Epub 2018 Jan 15.

15.

Exploiting Overlapping Advantages of In Vitro and In Cellulo Selection Systems to Isolate a Novel High-Affinity cJun Antagonist.

Baxter D, Ullman CG, Frigotto L, Mason JM.

ACS Chem Biol. 2017 Oct 20;12(10):2579-2588. doi: 10.1021/acschembio.7b00693. Epub 2017 Sep 7.

PMID:
28880076
16.

Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.

Szymiczek A, Carbone M, Pastorino S, Napolitano A, Tanji M, Minaai M, Pagano I, Mason JM, Pass HI, Bray MR, Mak TW, Yang H.

Oncogene. 2017 Nov 16;36(46):6501-6507. doi: 10.1038/onc.2017.266. Epub 2017 Jul 31.

17.

Erratum to: Comparison of the Simple Patient-Centric Atopic Dermatitis Scoring System PEST with SCORAD in Young Children Using a Ceramide Dominant Therapeutic Moisturizer.

Koh MJ, Giam YC, Liew HM, Foong AY, Chong JH, Wong SMY, Tang MBY, Ho MSL, Tan LS, Mason JM, Cork MJ.

Dermatol Ther (Heidelb). 2017 Sep;7(3):395. doi: 10.1007/s13555-017-0190-5. No abstract available.

18.

Downsizing Proto-oncogene cFos to Short Helix-Constrained Peptides That Bind Jun.

Baxter D, Perry SR, Hill TA, Kok WM, Zaccai NR, Brady RL, Fairlie DP, Mason JM.

ACS Chem Biol. 2017 Aug 18;12(8):2051-2061. doi: 10.1021/acschembio.7b00303. Epub 2017 Jun 21.

PMID:
28636317
19.

Comparison of the Simple Patient-Centric Atopic Dermatitis Scoring System PEST with SCORAD in Young Children Using a Ceramide Dominant Therapeutic Moisturizer.

Koh MJ, Giam YC, Liew HM, Foong AY, Chong JH, Wong SMY, Tang MBY, Ho MSL, Tan LS, Mason JM, Cork MJ.

Dermatol Ther (Heidelb). 2017 Sep;7(3):383-393. doi: 10.1007/s13555-017-0186-1. Epub 2017 Jun 14. Erratum in: Dermatol Ther (Heidelb). 2017 Jul 4;:.

20.

Colorectal cancer with Synchronous liver-limited Metastases: the protocol of an Inception Cohort study (CoSMIC).

Siriwardena AK, Chan AKC, Ignatowicz AM, Mason JM; CoSMIC study collaborators.

BMJ Open. 2017 Jun 9;7(6):e015018. doi: 10.1136/bmjopen-2016-015018.

21.

Steady-State Kinetics of α-Synuclein Ferrireductase Activity Identifies the Catalytically Competent Species.

McDowall JS, Ntai I, Hake J, Whitley PR, Mason JM, Pudney CR, Brown DR.

Biochemistry. 2017 May 16;56(19):2497-2505. doi: 10.1021/acs.biochem.7b00257. Epub 2017 May 4.

PMID:
28452474
22.

Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial.

Mason JM, Thomas KS, Ormerod AD, Craig FE, Mitchell E, Norrie J, Williams HC; U.K. Dermatology Clinical Trials Network's STOP GAP team.

Br J Dermatol. 2017 Dec;177(6):1527-1536. doi: 10.1111/bjd.15561. Epub 2017 May 31.

23.

Habit training versus habit training with direct visual biofeedback in adults with chronic constipation: study protocol for a randomised controlled trial.

Norton C, Emmanuel A, Stevens N, Scott SM, Grossi U, Bannister S, Eldridge S, Mason JM, Knowles CH.

Trials. 2017 Mar 24;18(1):139. doi: 10.1186/s13063-017-1880-0.

24.

Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.

Mason JM, Wei X, Fletcher GC, Kiarash R, Brokx R, Hodgson R, Beletskaya I, Bray MR, Mak TW.

Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3127-3132. doi: 10.1073/pnas.1700234114. Epub 2017 Mar 7.

25.

Computational Prediction and Design for Creating Iteratively Larger Heterospecific Coiled Coil Sets.

Crooks RO, Lathbridge A, Panek AS, Mason JM.

Biochemistry. 2017 Mar 21;56(11):1573-1584. doi: 10.1021/acs.biochem.7b00047. Epub 2017 Mar 13.

PMID:
28267310
26.

A Pooled Sequencing Approach Identifies a Candidate Meiotic Driver in Drosophila.

Wei KH, Reddy HM, Rathnam C, Lee J, Lin D, Ji S, Mason JM, Clark AG, Barbash DA.

Genetics. 2017 May;206(1):451-465. doi: 10.1534/genetics.116.197335. Epub 2017 Mar 3.

27.

Correction: Downsizing the BAD BH3 peptide to small constrained α-helices with improved ligand efficiency.

Shepherd NE, Harrison RS, Ruiz-Gomez G, Abbenante G, Mason JM, Fairlie DP.

Org Biomol Chem. 2016 Dec 28;14(48):11525. Epub 2016 Nov 23.

PMID:
27879976
28.

Oligonucleotide transition state analogues of saporin L3.

Mason JM, Yuan H, Evans GB, Tyler PC, Du Q, Schramm VL.

Eur J Med Chem. 2017 Feb 15;127:793-809. doi: 10.1016/j.ejmech.2016.10.059. Epub 2016 Oct 27.

29.

Downsizing the BAD BH3 peptide to small constrained α-helices with improved ligand efficiency.

Shepherd NE, Harrison RS, Ruiz-Gomez G, Abbenante G, Mason JM, Fairlie DP.

Org Biomol Chem. 2016 Nov 22;14(46):10939-10945.

PMID:
27819377
30.

Is speed of healing a good predictor of eventual healing of pyoderma gangrenosum?

Wilkes SR, Williams HC, Ormerod AD, Craig FE, Greenlaw N, Norrie J, Mitchell EJ, Mason JM, Thomas KS; United Kingdom Dermatology Clinical Trials Network STOP GAP team.

J Am Acad Dermatol. 2016 Dec;75(6):1216-1220.e2. doi: 10.1016/j.jaad.2016.07.049. Epub 2016 Oct 11.

PMID:
27742168
31.

Antibiotic use in acute pancreatitis: An audit of current practice in a tertiary centre.

Baltatzis M, Mason JM, Chandrabalan V, Stathakis P, McIntyre B, Jegatheeswaran S, Jamdar S, O'Reilly DA, Siriwardena AK.

Pancreatology. 2016 Nov - Dec;16(6):946-951. doi: 10.1016/j.pan.2016.08.012. Epub 2016 Aug 30.

PMID:
27613614
32.

Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.

Li SW, Liu Y, Sampson PB, Patel NK, Forrest BT, Edwards L, Laufer R, Feher M, Ban F, Awrey DE, Hodgson R, Beletskaya I, Mao G, Mason JM, Wei X, Luo X, Kiarash R, Green E, Mak TW, Pan G, Pauls HW.

Bioorg Med Chem Lett. 2016 Oct 1;26(19):4625-4630. doi: 10.1016/j.bmcl.2016.08.063. Epub 2016 Aug 23.

PMID:
27592744
33.

Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study.

Thomas KS, Ormerod AD, Craig FE, Greenlaw N, Norrie J, Mitchell E, Mason JM, Johnston GA, Wahie S, Williams HC; UK Dermatology Clinical Trials Network's STOP GAP Team.

J Am Acad Dermatol. 2016 Nov;75(5):940-949. doi: 10.1016/j.jaad.2016.06.016. Epub 2016 Aug 5.

34.

Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent.

Liu Y, Laufer R, Patel NK, Ng G, Sampson PB, Li SW, Lang Y, Feher M, Brokx R, Beletskaya I, Hodgson R, Plotnikova O, Awrey DE, Qiu W, Chirgadze NY, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Fletcher GC, Mak TW, Bray MR, Pauls HW.

ACS Med Chem Lett. 2016 May 6;7(7):671-5. doi: 10.1021/acsmedchemlett.5b00485. eCollection 2016 Jul 14.

35.

Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.

Laufer R, Li SW, Liu Y, Ng G, Lang Y, Feher M, Brokx R, Beletskaya I, Hodgson R, Mao G, Plotnikova O, Awrey DE, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Madeira B, Fletcher GC, Mak TW, Bray MR, Pauls HW.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3562-6. doi: 10.1016/j.bmcl.2016.06.021. Epub 2016 Jun 9.

PMID:
27335255
36.

Evidence based treatment for unstable slipped upper femoral epiphysis: Systematic review and exploratory patient level analysis.

Alshryda S, Tsang K, Chytas A, Chaudhry M, Sacchi K, Ahmad M, Mason JM.

Surgeon. 2018 Feb;16(1):46-54. doi: 10.1016/j.surge.2016.04.001. Epub 2016 May 30. Review.

PMID:
27255978
37.

Narrow band imaging optical diagnosis of small colorectal polyps in routine clinical practice: the Detect Inspect Characterise Resect and Discard 2 (DISCARD 2) study.

Rees CJ, Rajasekhar PT, Wilson A, Close H, Rutter MD, Saunders BP, East JE, Maier R, Moorghen M, Muhammad U, Hancock H, Jayaprakash A, MacDonald C, Ramadas A, Dhar A, Mason JM.

Gut. 2017 May;66(5):887-895. doi: 10.1136/gutjnl-2015-310584. Epub 2016 Apr 19.

38.

The SSTARS (STeroids and Stents Against Re-Stenosis) Trial: Different stent alloys and the use of peri-procedural oral corticosteroids to prevent in-segment restenosis after percutaneous coronary intervention.

Adam Z, Turley A, Mason JM, Kasim AS, Newby D, Mills N, Padfield G, Thompson L, Morley R, Hall JA, Wright RA, Muir DF, Sutton AG, Swanson N, Carter J, Bilous R, Jones S, de Belder MA.

Int J Cardiol. 2016 Aug 1;216:1-8. doi: 10.1016/j.ijcard.2016.04.105. Epub 2016 Apr 29.

PMID:
27135149
39.

Colorectal cancer with synchronous hepatic metastases: Systematic review of reports comparing synchronous surgery with sequential bowel-first or liver-first approaches.

Baltatzis M, Chan AK, Jegatheeswaran S, Mason JM, Siriwardena AK.

Eur J Surg Oncol. 2016 Feb;42(2):159-65. doi: 10.1016/j.ejso.2015.11.002. Epub 2015 Dec 20. Review.

PMID:
26733368
40.

Deriving Heterospecific Self-Assembling Protein-Protein Interactions Using a Computational Interactome Screen.

Crooks RO, Baxter D, Panek AS, Lubben AT, Mason JM.

J Mol Biol. 2016 Jan 29;428(2 Pt A):385-398. doi: 10.1016/j.jmb.2015.11.022. Epub 2015 Dec 2.

41.

Targeting Mitosis in Cancer: Emerging Strategies.

Dominguez-Brauer C, Thu KL, Mason JM, Blaser H, Bray MR, Mak TW.

Mol Cell. 2015 Nov 19;60(4):524-36. doi: 10.1016/j.molcel.2015.11.006. Review.

42.

Twenty-four hour infusion of human recombinant activated protein C (Xigris) early in severe acute pancreatitis: The XIG-AP 1 trial.

Miranda CJ, Mason JM, Babu BI, Sheen AJ, Eddleston JM, Parker MJ, Pemberton P, Siriwardena AK.

Pancreatology. 2015 Nov-Dec;15(6):635-41. doi: 10.1016/j.pan.2015.10.001. Epub 2015 Oct 20.

PMID:
26547592
43.

Toward peptide-based inhibitors as therapies for Parkinson's disease.

Mason JM, Fairlie DP.

Future Med Chem. 2015;7(16):2103-5. doi: 10.4155/fmc.15.139. Epub 2015 Oct 29. No abstract available.

PMID:
26510474
44.

Trans-anal irrigation therapy to treat adult chronic functional constipation: systematic review and meta-analysis.

Emmett CD, Close HJ, Yiannakou Y, Mason JM.

BMC Gastroenterol. 2015 Oct 16;15:139. doi: 10.1186/s12876-015-0354-7. Review.

45.

Risk of Ischaemic Heart Disease in Patients with Inflammatory Bowel Disease: Cohort Study Using the General Practice Research Database.

Close H, Mason JM, Wilson DW, Hungin AP, Jones R, Rubin G.

PLoS One. 2015 Oct 13;10(10):e0139745. doi: 10.1371/journal.pone.0139745. eCollection 2015.

46.

Recent evidence exploring the associations between physical activity and menopausal symptoms in midlife women: perceived risks and possible health benefits.

Pettee Gabriel K, Mason JM, Sternfeld B.

Womens Midlife Health. 2015 Aug 11;1:1. doi: 10.1186/s40695-015-0004-9. eCollection 2015. Review.

47.

Telomerase lost?

Mason JM, Randall TA, Capkova Frydrychova R.

Chromosoma. 2016 Mar;125(1):65-73. doi: 10.1007/s00412-015-0528-7. Epub 2015 Jul 11. Review.

48.

Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial.

Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, Mason JM, Walton S, Johnston GA, Williams HC; UK Dermatology Clinical Trials Network’s STOP GAP Team.

BMJ. 2015 Jun 12;350:h2958. doi: 10.1136/bmj.h2958. Erratum in: BMJ. 2017 Mar 21;356:j1462.

49.

Caffeine impairs resection during DNA break repair by reducing the levels of nucleases Sae2 and Dna2.

Tsabar M, Eapen VV, Mason JM, Memisoglu G, Waterman DP, Long MJ, Bishop DK, Haber JE.

Nucleic Acids Res. 2015 Aug 18;43(14):6889-901. doi: 10.1093/nar/gkv520. Epub 2015 May 27.

50.

Caffeine inhibits gene conversion by displacing Rad51 from ssDNA.

Tsabar M, Mason JM, Chan YL, Bishop DK, Haber JE.

Nucleic Acids Res. 2015 Aug 18;43(14):6902-18. doi: 10.1093/nar/gkv525. Epub 2015 May 27.

Supplemental Content

Loading ...
Support Center